Ibuprofen-in-cyclodextrin-in-W/O/W emulsion – Improving the initial and long-term encapsulation efficiency of a model active ingredient

[Display omitted] A challenge in formulating water-in-oil-in-water (W/O/W) emulsions is the uncontrolled release of the encapsulated compound prior to application. Pharmaceuticals and nutraceuticals usually have amphipathic nature, which may contribute to leakage of the active ingredient. In the pre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 2015-06, Vol.487 (1-2), p.1-7
Hauptverfasser: Hattrem, Magnus N., Kristiansen, Kåre A., Aachmann, Finn L., Dille, Morten J., Draget, Kurt I.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 7
container_issue 1-2
container_start_page 1
container_title International journal of pharmaceutics
container_volume 487
creator Hattrem, Magnus N.
Kristiansen, Kåre A.
Aachmann, Finn L.
Dille, Morten J.
Draget, Kurt I.
description [Display omitted] A challenge in formulating water-in-oil-in-water (W/O/W) emulsions is the uncontrolled release of the encapsulated compound prior to application. Pharmaceuticals and nutraceuticals usually have amphipathic nature, which may contribute to leakage of the active ingredient. In the present study, cyclodextrins (CyDs) were used to impart a change in the relative polarity and size of a model compound (ibuprofen) by the formation of inclusion complexes. Various inclusion complexes (2-hydroxypropyl (HP)-β-CyD-, α-CyD- and γ-CyD-ibuprofen) were prepared and presented within W/O/W emulsions, and the initial and long-term encapsulation efficiency was investigated. HP-β-CyD-ibuprofen provided the highest encapsulation of ibuprofen in comparison to a W/O/W emulsion with unassociated ibuprofen confined within the inner water phase, with a four-fold increase in the encapsulation efficiency. An improved, although lower, encapsulation efficiency was obtained for the inclusion complex γ-CyD-ibuprofen in comparison to HP-β-CyD-ibuprofen, whereas α-CyD-ibuprofen had a similar encapsulation efficiency to that of unassociated ibuprofen. The lower encapsulation efficiency of ibuprofen in combination with α-CyD and γ-CyD was attributed to a lower association constant for the γ-CyD-ibuprofen inclusion complex and the ability of α-CyD to form inclusion complexes with fatty acids. For the W/O/W emulsion prepared with HP-β-CyD-ibuprofen, the highest encapsulation of ibuprofen was obtained at hyper- and iso-osmotic conditions and by using an excess molar ratio of CyD to ibuprofen. In the last part of the study, it was suggested that the chemical modification of the HP-β-CyD molecule did not influence the encapsulation of ibuprofen, as a similar encapsulation efficiency was obtained for an inclusion complex prepared with mono-1-glucose-β-CyD.
doi_str_mv 10.1016/j.ijpharm.2015.03.059
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1680958903</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517315002756</els_id><sourcerecordid>1680958903</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-8cafc14f97ebeca012277f9688d0cb268a6e73505598583aed46ae7c73c836b33</originalsourceid><addsrcrecordid>eNqFUU1v1DAUtBAVXdr-BJCPXJK14_gjJ4QqPlaq1AtVj5bjvGy9SpzFdlbsjStn_iG_BKe7cOX05OeZN5oZhN5QUlJCxXpXut3-yYSxrAjlJWEl4c0LtKJKsoLVUrxEK8KkKjiV7BK9jnFHCBEVZa_QZcUVa2oqVujnpp33YerBF84X9miHqYPvKbjn9-P6fv2IYZyH6CaPf__4hTdjhh-c3-L0BNh5l5wZsPEdHia_LRKEEYO3Zh_nwaSFBX3vrMu7I556bPCYFTLDJndYDmwDdPk3XaOL3gwRbs7zCj18-vj19ktxd_95c_vhrrA1rVKhrOktrftGQgvWEFpVUvaNUKojtq2EMgIk44TzRmWXBrpaGJBWMquYaBm7Qu9Od7OPbzPEpEcXLQyD8TDNUVOhSMNVQxYoP0FtmGIM0Ot9cKMJR02JXlrQO31uQS8taMJ0biHz3p4l5naE7h_rb-wZ8P4EgGz04CDo-JxQTiKATbqb3H8k_gA_a560</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1680958903</pqid></control><display><type>article</type><title>Ibuprofen-in-cyclodextrin-in-W/O/W emulsion – Improving the initial and long-term encapsulation efficiency of a model active ingredient</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hattrem, Magnus N. ; Kristiansen, Kåre A. ; Aachmann, Finn L. ; Dille, Morten J. ; Draget, Kurt I.</creator><creatorcontrib>Hattrem, Magnus N. ; Kristiansen, Kåre A. ; Aachmann, Finn L. ; Dille, Morten J. ; Draget, Kurt I.</creatorcontrib><description>[Display omitted] A challenge in formulating water-in-oil-in-water (W/O/W) emulsions is the uncontrolled release of the encapsulated compound prior to application. Pharmaceuticals and nutraceuticals usually have amphipathic nature, which may contribute to leakage of the active ingredient. In the present study, cyclodextrins (CyDs) were used to impart a change in the relative polarity and size of a model compound (ibuprofen) by the formation of inclusion complexes. Various inclusion complexes (2-hydroxypropyl (HP)-β-CyD-, α-CyD- and γ-CyD-ibuprofen) were prepared and presented within W/O/W emulsions, and the initial and long-term encapsulation efficiency was investigated. HP-β-CyD-ibuprofen provided the highest encapsulation of ibuprofen in comparison to a W/O/W emulsion with unassociated ibuprofen confined within the inner water phase, with a four-fold increase in the encapsulation efficiency. An improved, although lower, encapsulation efficiency was obtained for the inclusion complex γ-CyD-ibuprofen in comparison to HP-β-CyD-ibuprofen, whereas α-CyD-ibuprofen had a similar encapsulation efficiency to that of unassociated ibuprofen. The lower encapsulation efficiency of ibuprofen in combination with α-CyD and γ-CyD was attributed to a lower association constant for the γ-CyD-ibuprofen inclusion complex and the ability of α-CyD to form inclusion complexes with fatty acids. For the W/O/W emulsion prepared with HP-β-CyD-ibuprofen, the highest encapsulation of ibuprofen was obtained at hyper- and iso-osmotic conditions and by using an excess molar ratio of CyD to ibuprofen. In the last part of the study, it was suggested that the chemical modification of the HP-β-CyD molecule did not influence the encapsulation of ibuprofen, as a similar encapsulation efficiency was obtained for an inclusion complex prepared with mono-1-glucose-β-CyD.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2015.03.059</identifier><identifier>PMID: 25839416</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage ; Biological Availability ; Chemistry, Pharmaceutical ; Cyclodextrin ; Cyclodextrins ; Drug Compounding ; Drug delivery ; Drug Storage ; Emulsions ; Encapsulation ; Gas Chromatography-Mass Spectrometry ; Ibuprofen - administration &amp; dosage ; Inclusion complex ; Oils - chemistry ; W/O/W emulsion ; Water - chemistry</subject><ispartof>International journal of pharmaceutics, 2015-06, Vol.487 (1-2), p.1-7</ispartof><rights>2015 Elsevier B.V.</rights><rights>Copyright © 2015 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-8cafc14f97ebeca012277f9688d0cb268a6e73505598583aed46ae7c73c836b33</citedby><cites>FETCH-LOGICAL-c412t-8cafc14f97ebeca012277f9688d0cb268a6e73505598583aed46ae7c73c836b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijpharm.2015.03.059$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25839416$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hattrem, Magnus N.</creatorcontrib><creatorcontrib>Kristiansen, Kåre A.</creatorcontrib><creatorcontrib>Aachmann, Finn L.</creatorcontrib><creatorcontrib>Dille, Morten J.</creatorcontrib><creatorcontrib>Draget, Kurt I.</creatorcontrib><title>Ibuprofen-in-cyclodextrin-in-W/O/W emulsion – Improving the initial and long-term encapsulation efficiency of a model active ingredient</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted] A challenge in formulating water-in-oil-in-water (W/O/W) emulsions is the uncontrolled release of the encapsulated compound prior to application. Pharmaceuticals and nutraceuticals usually have amphipathic nature, which may contribute to leakage of the active ingredient. In the present study, cyclodextrins (CyDs) were used to impart a change in the relative polarity and size of a model compound (ibuprofen) by the formation of inclusion complexes. Various inclusion complexes (2-hydroxypropyl (HP)-β-CyD-, α-CyD- and γ-CyD-ibuprofen) were prepared and presented within W/O/W emulsions, and the initial and long-term encapsulation efficiency was investigated. HP-β-CyD-ibuprofen provided the highest encapsulation of ibuprofen in comparison to a W/O/W emulsion with unassociated ibuprofen confined within the inner water phase, with a four-fold increase in the encapsulation efficiency. An improved, although lower, encapsulation efficiency was obtained for the inclusion complex γ-CyD-ibuprofen in comparison to HP-β-CyD-ibuprofen, whereas α-CyD-ibuprofen had a similar encapsulation efficiency to that of unassociated ibuprofen. The lower encapsulation efficiency of ibuprofen in combination with α-CyD and γ-CyD was attributed to a lower association constant for the γ-CyD-ibuprofen inclusion complex and the ability of α-CyD to form inclusion complexes with fatty acids. For the W/O/W emulsion prepared with HP-β-CyD-ibuprofen, the highest encapsulation of ibuprofen was obtained at hyper- and iso-osmotic conditions and by using an excess molar ratio of CyD to ibuprofen. In the last part of the study, it was suggested that the chemical modification of the HP-β-CyD molecule did not influence the encapsulation of ibuprofen, as a similar encapsulation efficiency was obtained for an inclusion complex prepared with mono-1-glucose-β-CyD.</description><subject>Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage</subject><subject>Biological Availability</subject><subject>Chemistry, Pharmaceutical</subject><subject>Cyclodextrin</subject><subject>Cyclodextrins</subject><subject>Drug Compounding</subject><subject>Drug delivery</subject><subject>Drug Storage</subject><subject>Emulsions</subject><subject>Encapsulation</subject><subject>Gas Chromatography-Mass Spectrometry</subject><subject>Ibuprofen - administration &amp; dosage</subject><subject>Inclusion complex</subject><subject>Oils - chemistry</subject><subject>W/O/W emulsion</subject><subject>Water - chemistry</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUU1v1DAUtBAVXdr-BJCPXJK14_gjJ4QqPlaq1AtVj5bjvGy9SpzFdlbsjStn_iG_BKe7cOX05OeZN5oZhN5QUlJCxXpXut3-yYSxrAjlJWEl4c0LtKJKsoLVUrxEK8KkKjiV7BK9jnFHCBEVZa_QZcUVa2oqVujnpp33YerBF84X9miHqYPvKbjn9-P6fv2IYZyH6CaPf__4hTdjhh-c3-L0BNh5l5wZsPEdHia_LRKEEYO3Zh_nwaSFBX3vrMu7I556bPCYFTLDJndYDmwDdPk3XaOL3gwRbs7zCj18-vj19ktxd_95c_vhrrA1rVKhrOktrftGQgvWEFpVUvaNUKojtq2EMgIk44TzRmWXBrpaGJBWMquYaBm7Qu9Od7OPbzPEpEcXLQyD8TDNUVOhSMNVQxYoP0FtmGIM0Ot9cKMJR02JXlrQO31uQS8taMJ0biHz3p4l5naE7h_rb-wZ8P4EgGz04CDo-JxQTiKATbqb3H8k_gA_a560</recordid><startdate>20150620</startdate><enddate>20150620</enddate><creator>Hattrem, Magnus N.</creator><creator>Kristiansen, Kåre A.</creator><creator>Aachmann, Finn L.</creator><creator>Dille, Morten J.</creator><creator>Draget, Kurt I.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150620</creationdate><title>Ibuprofen-in-cyclodextrin-in-W/O/W emulsion – Improving the initial and long-term encapsulation efficiency of a model active ingredient</title><author>Hattrem, Magnus N. ; Kristiansen, Kåre A. ; Aachmann, Finn L. ; Dille, Morten J. ; Draget, Kurt I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-8cafc14f97ebeca012277f9688d0cb268a6e73505598583aed46ae7c73c836b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage</topic><topic>Biological Availability</topic><topic>Chemistry, Pharmaceutical</topic><topic>Cyclodextrin</topic><topic>Cyclodextrins</topic><topic>Drug Compounding</topic><topic>Drug delivery</topic><topic>Drug Storage</topic><topic>Emulsions</topic><topic>Encapsulation</topic><topic>Gas Chromatography-Mass Spectrometry</topic><topic>Ibuprofen - administration &amp; dosage</topic><topic>Inclusion complex</topic><topic>Oils - chemistry</topic><topic>W/O/W emulsion</topic><topic>Water - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hattrem, Magnus N.</creatorcontrib><creatorcontrib>Kristiansen, Kåre A.</creatorcontrib><creatorcontrib>Aachmann, Finn L.</creatorcontrib><creatorcontrib>Dille, Morten J.</creatorcontrib><creatorcontrib>Draget, Kurt I.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hattrem, Magnus N.</au><au>Kristiansen, Kåre A.</au><au>Aachmann, Finn L.</au><au>Dille, Morten J.</au><au>Draget, Kurt I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ibuprofen-in-cyclodextrin-in-W/O/W emulsion – Improving the initial and long-term encapsulation efficiency of a model active ingredient</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2015-06-20</date><risdate>2015</risdate><volume>487</volume><issue>1-2</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted] A challenge in formulating water-in-oil-in-water (W/O/W) emulsions is the uncontrolled release of the encapsulated compound prior to application. Pharmaceuticals and nutraceuticals usually have amphipathic nature, which may contribute to leakage of the active ingredient. In the present study, cyclodextrins (CyDs) were used to impart a change in the relative polarity and size of a model compound (ibuprofen) by the formation of inclusion complexes. Various inclusion complexes (2-hydroxypropyl (HP)-β-CyD-, α-CyD- and γ-CyD-ibuprofen) were prepared and presented within W/O/W emulsions, and the initial and long-term encapsulation efficiency was investigated. HP-β-CyD-ibuprofen provided the highest encapsulation of ibuprofen in comparison to a W/O/W emulsion with unassociated ibuprofen confined within the inner water phase, with a four-fold increase in the encapsulation efficiency. An improved, although lower, encapsulation efficiency was obtained for the inclusion complex γ-CyD-ibuprofen in comparison to HP-β-CyD-ibuprofen, whereas α-CyD-ibuprofen had a similar encapsulation efficiency to that of unassociated ibuprofen. The lower encapsulation efficiency of ibuprofen in combination with α-CyD and γ-CyD was attributed to a lower association constant for the γ-CyD-ibuprofen inclusion complex and the ability of α-CyD to form inclusion complexes with fatty acids. For the W/O/W emulsion prepared with HP-β-CyD-ibuprofen, the highest encapsulation of ibuprofen was obtained at hyper- and iso-osmotic conditions and by using an excess molar ratio of CyD to ibuprofen. In the last part of the study, it was suggested that the chemical modification of the HP-β-CyD molecule did not influence the encapsulation of ibuprofen, as a similar encapsulation efficiency was obtained for an inclusion complex prepared with mono-1-glucose-β-CyD.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>25839416</pmid><doi>10.1016/j.ijpharm.2015.03.059</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2015-06, Vol.487 (1-2), p.1-7
issn 0378-5173
1873-3476
language eng
recordid cdi_proquest_miscellaneous_1680958903
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
Biological Availability
Chemistry, Pharmaceutical
Cyclodextrin
Cyclodextrins
Drug Compounding
Drug delivery
Drug Storage
Emulsions
Encapsulation
Gas Chromatography-Mass Spectrometry
Ibuprofen - administration & dosage
Inclusion complex
Oils - chemistry
W/O/W emulsion
Water - chemistry
title Ibuprofen-in-cyclodextrin-in-W/O/W emulsion – Improving the initial and long-term encapsulation efficiency of a model active ingredient
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T02%3A51%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ibuprofen-in-cyclodextrin-in-W/O/W%20emulsion%20%E2%80%93%20Improving%20the%20initial%20and%20long-term%20encapsulation%20efficiency%20of%20a%20model%20active%20ingredient&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Hattrem,%20Magnus%20N.&rft.date=2015-06-20&rft.volume=487&rft.issue=1-2&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2015.03.059&rft_dat=%3Cproquest_cross%3E1680958903%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1680958903&rft_id=info:pmid/25839416&rft_els_id=S0378517315002756&rfr_iscdi=true